// App-Quantinova.ai

3024 : A Phase 1b-2 Study of KRT-232, a First-in-Class, Oral, Small Molecule Inhibitor of Murine Double Minute 2 (MDM2), in Combination with Acalabrutinib for the Treatment of Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Researchers

Presenter

  • Peter Hillmen

Principal Investigators

  • Hope Qamoos

  • Anne Uyei

  • Wayne M. Rothbaum

  • Wojciech Jurczak

  • Catherine Thieblemont

  • John C. Byrd

Medical Centers

  • St. James's University Hospital, Leeds, United Kingdom

  • Kartos Therapeutics, Inc., Redwood City, CA

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Hospital Saint Antoine, Paris, France

  • The Ohio State Univerisity, Columbus, OH

Locations

  • United Kingdom

  • United States

  • Poland

  • France

Companies

  • Kartos Therapeutics,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Chronic Lymphocytic Leukemia

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Mouse double minute 2 homolog

  • Tumor protein p53

Drug/Treatment

  • ACP-196

  • KRT-232

  • TP53

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved